Dosimetry for Radiopeptide Therapy

Dosimetry is an important asset in the therapy of neuro-endocrine tumours with radiolabelled peptides. Initially therapy was performed with 90Y-DOTA-octreotide with good results, but many cases of severe kidney damage have been observed due to the difficulty in performing accurate dosimetry for this pure β-emitter. Therapy with 177Lu-DOTA-octreotate does offer the possibility of performing dosimetry assessments by its emission of two γ-rays at 113 and 208 keV. Nevertheless, this last product was granted worldwide market authorization on a fixed activity administration scheme after very successful grade 3 trials showing prolonged progression free and overall survival with good quality of life in comparison to conventional treatments. Peptide Receptor Radionuclide Therapy (PRRT) forms the second-line treatment for neuroendocrine tumours.